CSE1L and non-small cell lung carcinoma: Our findings also suggest that p53 wild-type NSCLC cells that exhibit elevated expression levels of CSE1L and AURKA pathway genes may be particularly responsive to the HDAC1/2 inhibitor mocetinostat.